Physician profile
Sergio Quijano
NPI 1609033216
$8,920.48
in general payments reported to CMS, 2019-2025
31 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $582 · 2021: $1,384 · 2022: $902 · 2023: $3,406 · 2024: $762 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,160 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,928.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,160.00 |
| Education | $126.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,392.70 | 2023-2024 | Iqirvo |
| Abbvie INC. | $2,027.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,704.32 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $546.09 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $431.92 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $296.18 | 2019-2025 | |
| Boston Scientific Corporation | $186.10 | 2023-2025 | Exalt Model D, General - Metal Stents - G.I. |
| Madrigal Pharmaceuticals | $139.35 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $132.40 | 2021 | |
| Pfizer INC. | $132.39 | 2019-2025 | |
| Celgene Corporation | $121.25 | 2021-2024 | Zeposia |
| Romark Laboratories, Lc | $113.05 | 2019-2020 | |
| Qol Medical, LLC | $93.89 | 2019-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $81.52 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $63.07 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $59.27 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $52.35 | 2021-2022 | |
| Novo Nordisk INC | $49.71 | 2025 | Wegovy |
| Redhill Biopharma INC. | $34.63 | 2022 | |
| Merck Sharp & Dohme LLC | $31.14 | 2019-2021 | |
| Allergan, INC. | $30.70 | 2019 | |
| Alfasigma USA, INC. | $29.25 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.60 | 2024 | Dupixent |
| Ardelyx, INC. | $25.50 | 2023 | Ibsrela |
| Ucb, INC. | $22.79 | 2019 | |
| Ironwood Pharmaceuticals, INC | $19.30 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.15 | 2023 | |
| Genzyme Corporation | $17.90 | 2025 | |
| Fresenius Kabi USA, LLC | $17.56 | 2023 | Idacio |
| Evoke Pharma, INC. | $13.52 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Quijano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.